MAPT and proteostasis deficiencies: Indeed, previous studies in proteinopathies showed that Nrf2 activation inhibited the formation and/or reduced the number of existing aggregates of α-synuclein [[97], [98], [99], [100]], amyloid beta [[101], [102], [103], [104]] and tau [[105], [106], [107]], whereas Nrf2 deficiency promotes protein aggregation [[108], [109], [110]].